抗酸剂市场 - 按药物类别（质子帮浦抑制剂、酸中和剂、抗幽门螺旋桿菌药物）、适应症（胃食道逆流、胃灼热、胃炎）、剂量、给药途径、配销通路-全球预测（2024 - 2032）

由于配方和给药方法的进步，2024 年至 2032 年间，全球抗酸剂市场规模将以 5.1% 的复合年增长率扩大。咀嚼片、即溶粉剂和方便的液体形式等创新增强了抗酸剂的有效性和使用者体验。此外，人们对消化系统健康的认识不断提高，消化系统疾病的发生率也越来越高，促使消费者寻求有效的非处方解决方案。技术进步和健康意识增强相结合，促进了对多样化和先进抗酸产品的需求不断增长，推动了市场扩张。

例如，2024年6月，Akums Drugs & Pharmaceuticals Ltd.推出了一款含有海藻酸钠和碳酸氢钾的新型抗反流咀嚼片，该片剂已获得印度药品监管总局（DCGI）的批准。这项创新反映了抗酸剂配方的不断进步，满足了对有效、用户友好的消化解决方案日益增长的需求。这项批准凸显了监管机构对新型抗酸产品的支持不断增加，而此类先进配方的推出可以透过提供增强的缓解方案和扩大全球消费者的选择来推动市场成长。

抗酸剂产业根据药物类别、适应症、剂量、给药途径、配销通路和地区而分散。

由于酸中和剂在缓解胃灼热和胃酸消化不良方面的即时效果，到 2032 年，酸中和剂市场将显着成长。这些产品包括碳酸钙和氢氧化镁，透过直接中和胃酸发挥作用，从而快速缓解症状。它们在柜檯上广泛销售，并被消费者接受为消化不适的快速解决方案，这有助于它们占据市场主导地位。胃食道逆流（GERD）的日益普及进一步增加了对酸中和剂的需求。

由于胃灼热在成年人中广泛发生，到 2032 年，胃灼热细分市场将显着改善。胃灼热通常由胃食道逆流症 (GERD) 引起，这推动了对可快速有效缓解症状的非处方抗酸剂的巨大需求。片剂、液体剂和咀嚼片等各种配方的推出满足了不同消费者的喜好，进一步促进了市场成长。此外，人们对控制胃灼热症状的认识的提高和自我药疗的便利性也有助于该细分市场的主导地位。

由于该地区消化系统疾病的高发生率和医疗保健意识的不断增强，亚太地区抗酸剂市场份额从 2024 年到 2032 年将经历显着的复合年增长率。快速的城市化、饮食习惯的改变和压力水平的增加导致中国和印度等国家胃灼热和胃酸倒流的发病率上升。此外，不断扩大的中产阶级人口和医疗保健产品的普及正在推动抗酸剂的需求。该地区日益关註消化系统健康管理，有效地使亚太地区成为抗酸剂产业的重要贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 胃肠道疾病盛行率上升
    • 饮食和生活方式的改变
    • 提高意识和自我药疗
    • 製药进步
  • 产业陷阱与挑战
    • 副作用和健康风险
    • 替代品的可用性
• 成长潜力分析
• 技术景观
• 监管环境
• 2023 年定价分析
  • 按地区
  • 按关键人物
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 质子帮浦抑制剂
• 酸中和剂
• 抗幽门螺旋桿菌药物
• H2拮抗剂
• 促动力剂
• 前列腺素类似物
• 其他药物类别

第 6 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 胃食道逆流疾病
• 胃灼热
• 消化不良
• 胃炎
• 消化性溃疡病
• 其他适应症

第 7 章：市场估计与预测：按剂量，2021 - 2032

• 主要趋势
• 平板电脑
• 液体
• 其他剂量

第 8 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
• 口服
• 可注射

第 9 章：市场估计与预测：按配销通路，2021 - 2032

• 主要趋势
• 医院药房
• 网路药房
• 零售药房

第 10 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• Aurobindo Pharma Limited
• Bayer AG
• Bristol Myers Squibb Company
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Gsk plc
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd
• The Procter & Gamble Company
• Viatris Inc.

Global Antacids Market size will expand at a 5.1% CAGR between 2024 and 2032, attributed to advances in formulation and delivery methods. Innovations such as chewable tablets, fast-dissolving powders, and convenient liquid forms enhance the effectiveness and user experience of antacids. Furthermore, greater awareness about digestive health and the heightened rate of digestive disorders encourages consumers to seek effective over-the-counter solutions. This combination of technological improvements and increased health consciousness contributes to a rising demand for diverse and advanced antacid products, fueling market expansion.

For instance, in June 2024, Akums Drugs & Pharmaceuticals Ltd. launched a new anti-reflux chewable tablet containing sodium alginate and potassium bicarbonate, which has been approved by the Drugs Controller General of India (DCGI). This innovation reflects growing advancements in antacid formulations, catering to the increasing demand for effective, user-friendly digestive solutions. The approval highlights the rising regulatory support for new antacid products, while the introduction of such advanced formulations can drive market growth by offering enhanced relief options and expanding consumer choice globally.

The antacids industry is fragmented based on drug class, indication, dosage, route of administration, distribution channel, and region.

The acid neutralizers segment will observe a noteworthy surge through 2032, spurred by their immediate effectiveness in relieving heartburn and acid indigestion. These products, which include calcium carbonate and magnesium hydroxide, work by directly neutralizing stomach acid, providing rapid symptom relief. Their widespread availability over the counter and acceptance by consumers as a quick solution for digestive discomfort contribute to their dominant market position. The growing prevalence of gastroesophageal reflux disease (GERD) further boosts the demand for acid neutralizers.

The heartburn segment will undergo a remarkable upturn by 2032, owing to the widespread occurrence of this condition among adults. Heartburn, often caused by gastroesophageal reflux disease (GERD), drives a significant demand for over-the-counter antacids that provide quick and effective relief. The availability of various formulations, such as tablets, liquids, and chewables, caters to diverse consumer preferences, further boosting market growth. Also, increasing awareness about managing heartburn symptoms and the convenience of self-medication contribute to the segment's dominance.

Asia Pacific antacids market share will experience a notable CAGR from 2024 to 2032 due to the region's high prevalence of digestive disorders and growing healthcare awareness. Rapid urbanization, changing dietary habits, and increased stress levels contribute to the rising incidence of heartburn and acid reflux in countries like China and India. Besides, the expanding middle-class population and improved access to healthcare products are driving the demand for antacids. The region's growing focus on managing digestive health effectively positions Asia Pacific as a crucial contributor to the antacids industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of gastrointestinal disorders
    • 3.2.1.2 Dietary and lifestyle changes
    • 3.2.1.3 Increased awareness and self-medication
    • 3.2.1.4 Pharmaceutical advancements
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and health risks
    • 3.2.2.2 Availability of substitutes
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Pricing analysis, 2023
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Proton pump inhibitors
• 5.3 Acid neutralizers
• 5.4 Anti-H.pyloric drugs
• 5.5 H2 antagonists
• 5.6 Pro-motility agents
• 5.7 Prostaglandin analogous
• 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Gastroesophageal reflux disease
• 6.3 Heartburn
• 6.4 Indigestion
• 6.5 Gastritis
• 6.6 Peptic ulcer disease
• 6.7 Other indications

Chapter 7 Market Estimates and Forecast, By Dosage, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Tablets
• 7.3 Liquid
• 7.4 Other dosages

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Injectable

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacy
• 9.3 Online pharmacy
• 9.4 Retail pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Aurobindo Pharma Limited
• 11.2 Bayer AG
• 11.3 Bristol Myers Squibb Company
• 11.4 Cipla Limited
• 11.5 Dr. Reddy's Laboratories Ltd.
• 11.6 F. Hoffmann-La Roche Ltd.
• 11.7 Gsk plc
• 11.8 Hikma Pharmaceuticals PLC
• 11.9 Lupin Limited
• 11.10 Novartis AG
• 11.11 Pfizer Inc.
• 11.12 Sun Pharmaceutical Industries Ltd
• 11.13 Teva Pharmaceutical Industries Ltd
• 11.14 The Procter & Gamble Company
• 11.15 Viatris Inc.